UTI Mutual Fund (MF) purchased 1.52 lakh equity shares or 0.1121% stake in Eris Lifesciences on 19 May 2021.
Post transaction, UTI Mutual Fund (UTI MF) increased its shareholding to 5.0583% stake from 4.9462% held earlier. The deal was executed in secondary market on 19 May 2021.
Eris Lifesciences' consolidated net profit jumped 21.3% to Rs 68.25 crore on a 12.4% surge in net sales to Rs 274.25 crore in Q4 March 2021 over Q4 March 2020.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.
The scrip rose 0.01% to Rs 716 on BSE. It traded in the range of 716 and 735 so far during the day.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app